These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25893522)

  • 1. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor-kappa B (RANK) Signaling.
    Golden D; Saria EA; Hansen MF
    J Cell Physiol; 2015 Dec; 230(12):2951-60. PubMed ID: 25893522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells.
    Beristain AG; Narala SR; Di Grappa MA; Khokha R
    J Cell Sci; 2012 Feb; 125(Pt 4):943-55. PubMed ID: 22421365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin activates osteosarcoma cells that co-express RANK and RANKL.
    Marley K; Bracha S; Seguin B
    Exp Cell Res; 2015 Oct; 338(1):32-8. PubMed ID: 26254896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain.
    Kusumi A; Sakaki H; Kusumi T; Oda M; Narita K; Nakagawa H; Kubota K; Satoh H; Kimura H
    J Bone Miner Metab; 2005; 23(5):373-81. PubMed ID: 16133687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2.
    Nadiminty N; Lou W; Lee SO; Mehraein-Ghomi F; Kirk JS; Conroy JM; Zhang H; Gao AC
    Clin Cancer Res; 2006 Mar; 12(5):1420-30. PubMed ID: 16533764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro.
    Zhang S; Wang X; Li G; Chong Y; Zhang J; Guo X; Li B; Bi Z
    Mol Med Rep; 2017 Oct; 16(4):3994-4000. PubMed ID: 28731168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
    Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
    J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
    Lai TH; Fong YC; Fu WM; Yang RS; Tang CH
    Prostate; 2008 Sep; 68(12):1341-53. PubMed ID: 18512729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
    Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
    J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol protects against ethanol-induced bone loss by inhibiting up-regulation of receptor activator of nuclear factor-kappaB ligand in osteoblasts.
    Chen JR; Haley RL; Hidestrand M; Shankar K; Liu X; Lumpkin CK; Simpson PM; Badger TM; Ronis MJ
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1182-90. PubMed ID: 16971503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.